|All Time High:
|The price of #CTI today is $0.016 USD.
The lowest CTI price for this period was $0, the highest was $0.016, and the current live price for one CTI coin is $0.01591.
The all-time high CTI coin price was $0.42.
Use our custom price calculator to see the hypothetical price of CTI with market cap of ETH or other crypto coins.
|The code for ClinTex CTi crypto currency is #CTI.
ClinTex CTi is 3.1 years old.
|The current market capitalization for ClinTex CTi is $3,044,390.
ClinTex CTi is ranking upwards to #761 out of all coins, by market cap (and other factors).
|There is a medium daily trading volume on #CTI.
Today's 24-hour trading volume across all exchanges for ClinTex CTi is $287,432.
|The circulating supply of CTI is 191,311,840 coins, which is 100% of the total coin supply.
CTAi Beta Release Imminent
We have been working tirelessly over the previous months on the development of our groundbreaking Clintex CTAi application. For those who do not know, Clintex CTAi is a natural language processing (NLP) app that helps the user seamlessly interact with their data to produce valuable insights and visualisations. It is part of the Clinical Trials Intelligence (CTi) platform. CTAi is designed to be used with no prior experience in data science or programming. Users can simply ask questions in plain English and CTAi will return the answer in the form of data and visuals. This makes it easy for users to gain the insights they need in order to make better decisions pertaining to a particular clinical trial they are working on. The Innovative CTAi application is nearing its beta release in the next few weeks. This release will include all the minimum viable product (MVP) features, allowing clinicians and non-programmers to interact with and explore clinical data using a pre-defined library of visuals. It’s natural language processing engine seamlessly converts clinical questions into scripts that query the data and produce intuitive charts and tables to enable decision-making throughout the life of a clinical trial. Any question that a clinical trial professional may have about the trial can be asked instantly, without the need for complex programming. This truly represents a paradigm shift in the oversight of clinical trials and ...
ClinTex Q2–2023 Update
CTAi - The use of artificial intelligence (AI) in clinical trials is rapidly gaining momentum, as researchers and pharmaceutical companies alike recognize the potential of this technology to revolutionize the drug development process. One of the key benefits of AI is its ability to process large amounts of data quickly and efficiently. This is essential in clinical trials, where researchers need to collect and analyse vast amounts of data in order to make informed decisions about the safety and efficacy of new drugs. AI can help to automate many of the tasks involved in data collection and analysis, freeing up researchers to focus on other aspects of the trial. In addition to processing data more quickly, AI can also help to identify patterns and trends that would be difficult to spot with the naked eye. This can be invaluable in early-stage clinical trials, where researchers are trying to determine whether a new drug is even worth pursuing. By using AI to analyse data, researchers can identify promising leads more quickly and efficiently, which can lead to faster drug development. ClinTex is one project that is leading the way in the development of AI powered clinical trial data solutions. The company’s CTAi app is designed to help medics seamlessly interact with their data to produce valuable insights and visualisations. This is an exciting development for the industry, as it means that medics do not need to rely on data ...
Australian Regulator approves MDMA for PTSD treatment
Australia made history on July 1, 2023, when it became the first country in the world to prescribe MDMA and psilocybin for therapeutic use. The Therapeutic Goods Administration (TGA), Australia’s medicines regulator, approved the use of MDMA for the treatment of post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression. The decision to approve these drugs for therapeutic use was based on the results of clinical trials that showed that both MDMA and psilocybin can be effective in treating these conditions. In the case of MDMA, the drug was shown to be effective in reducing the symptoms of PTSD in people who had not responded to other treatments. Psilocybin, on the other hand, was shown to be effective in reducing the symptoms of treatment-resistant depression in people who had not responded to other treatments. The adoption of the use of these drugs in Australia is great news for the Clintex team as we eagerly await the start of the LVL CANPAIN trial. The movement in other novel forms of treatment for other coditions can only benefit the CANPAIN trial and everybody involved including Clintex. LVL Health, a clinical-stage pharmaceutical company developing novel treatments for chronic pain, last year announced a collaboration with Clintex CTI. Clintex will provide its expertise and insights to LVL Health’s CANPAIN trial, a Phase 2b trial evaluating the efficacy and safety of LVL-101 for the treat...
AI-based Clinical Trials market to grow by 600% before end of the decade
According to a new study from Research and Markets, the global market for AI-based clinical trial solutions for patient matching is expected to reach USD$1,969 million by 2030. This growth is fueled by sustained and increased investment in AI-based technologies to deliver higher efficiency and improve operational processes in clinical trials, as well as an increased use of advanced technologies such as Artificial Intelligence (AI), Machine Learning (ML), and deep learning to support a more efficient clinical trial process. Traditional R&D processes are known to be time-consuming, costly, and require significant investment. Because of the high development costs, pharmaceutical and biotech companies are increasingly incorporating artificial intelligence (AI) into their research and development efforts in order to reduce costs, improve data quality, and shorten trial lengths. According to Deloitte, “Artificial intelligence (AI)-enabled data collection and management can be a game changer for life sciences companies in the drug development process.” These are the problems and solutions that companies like Clintex are exploring through the use of the Clinical Trial Intelligence Tool (CTi).www.researchandmarkets.com Clintex is at the forefront of AI-based clinical trial solutions and we believe that Artificial Intelligence (AI) and machine learning techniques have great potential to improve clinical trial efficiencies and e...
How AI will drive success in Clinical Trials
It takes up to 15 years and an average total R&D expenditure of $1.5–2 billion USD to bring a single new drug to market. About half of this investment is spent on clinical trials, with Phase III trials being the most complex and most expensive. Probabilities of success for compounds to proceed through the clinical trial stages vary from phase to phase, and lead to a situation where only 10% of compounds entering clinical trials advances to FDA approval. High clinical trial failure rates are one major cause for the prevailing inefficiency of the drug development cycle. Artificial intelligence (AI) has been a hot topic in the medical field for some time now. Some may view it as just another fad, but the truth is that AI has the potential to revolutionize the way we conduct clinical trials and discover new medicines. Two of the key factors causing a clinical trial to be unsuccessful are patient cohort selection and recruiting mechanisms which fail to bring the best suited patients to a trial in time. This potential financial loss is an incentive for pharmaceutical companies to use artificial intelligence (AI) technologies in the initial stages of clinical trials. AI technology can examine large amounts of data to detect patient subgroups that might benefit more in a clinical trial. It can also analyse social media content to identify specific regions where a condition is more prevalent, thus narrowing down the search for t...
ClinTex 2023 Roadmap
Over the past few weeks we have been meeting internally to define our strategy and goals in the runup to the new year. To this end we published the outline of our 2023 updated roadmap on the ClinTex homepage. Allow us a moment to briefly dive a little deeper into the next stages of the ClinTex plan. In 2023 ClinTex will focus on the development of indication-specific visuals and analytics to support clinical trials in the treatment of chronic pain. Q1 — Establish Core Packages to standardise and streamline analytics development using Optex technology. CTi to launch CTi Core Visualisations into Market. Via Optex, the CTi Visualisation Core will run completely decentralised, on-chain on top of the Internet Computer (ICP). Q2 — Development of visuals and analytics to directly support oversight of primary and secondary endpoints for a Phase III clinical trial for treatment of Chronic Pain. This is the final development sprint in preparation for go-to-market full live launch. Q3 — CTi Development Testing in a live trial environment. CTi Mainnet Quality Assurance Testing & User Acceptance Testing Q4 — Clintex CTi deployment in a live chronic pain clinical trials, including Clintex Data Management Consultancy Services (*). CTi Live Deployment including licencing mechanism — token CTi token utility goes live on client trial services, including token burn mechanism on licence expiry. *Consultanc...
ClinTex sign Letter of Intent with LVL Health
Clintex are excited to announce the signing of an agreement with LVL Health (lvlhealth.co.uk) to support their CANPAIN clinical trial (clinicaltrials.gov) evaluating Cannabis Based Medicinal Products (CBMPs) in the treatment of Chronic Pain. This clinical trial is particularly high profile as it is being conducted to provide key data to NICE (National Institute for Care & Excellence) to prove the benefits of medical cannabis and enable prescription of CBMPs for chronic pain patients on the NHS. This therefore represents a major opportunity to showcase ClinTex CTi technology and demonstrate how it can help support accelerated patient access to much needed treatments. Previously Clintex, LVL Health and Celadon Pharmaceuticals have held a number of exploratory discussions and have arrived at a clear consensus on how the CTi platform and the clinical trial expertise at Clintex can support this high profile CANPAIN clinical trial. As a result, Clintex intend to provide certain services to LVL Health and the CANPAIN clinical trial including, but not limited to: Deployment of CTi through the creation and maintenance of CANPAIN specific data visuals to support oversight and instream insights into the main trial assessing CBMP for the treatment of non-cancer chronic pain, Consultancy on the data management strategy relating to the CANPAIN trial including liaising with Contract Research Organisations (CROs) and other vendors to o...
Q4–2022 at ClinTex HQ
The autumnal months have begun to set in here in Europe as the crypto bear market drags on, mirroring the wider global macro economic uncertainty that has been so evident thus far in 2022. To say it has been a tumultuous year so far would be an understatement, however here at ClinTex during our 9–5 working day we try not to let the market swings and roundabouts get us down nor affect our focus. The important thing, as we have learned from previous market cycles, is to stay fixed on our long term objectives. — Raydium LP - One of the emerging areas of crypto technology which we have been consistently impressed with this year has been the Solana blockchain. Although not without its teething problems, it is showing enormous promise by providing lightning fast transactions for fractions of a cent. This has brought with it the possibility to build highly efficient decentralized exchanges (DEXs) such as Raydium. We spoke on the launch of CTI2.0 about providing more potential cross-chain trading opportunities for our users and this one was high on our list for further investigation. We are now on track to have our Raydium liquidity pool online by the 15th of October. Details about how to trade on this new exchange once live will be posted here on Medium and as always, users can head into our official Telegram channel for more help if needed. — OpTex - One of the most important aspects of our production schedule over th...
ClinTex in discussions with Celadon Pharmaceuticals and LVL Health
We are extremely excited to announce that ClinTex are currently in active discussions with two ground breaking companies, to support clinical trials in the application of medicinal cannabis to manage chronic pain. Celadon Pharmaceuticals recently released a substantial business update since announcing to become the first British cannabis company since GW Pharmaceuticals to list on the Alternative Investments Market (AIM) in March of this year. Celadon became one of the first companies in the UK to receive a Home Office license to grow high-THC cannabis and as of May the company says it has now produced six batches at its 100,000 sq. ft facility in the Midlands. For more information on Celadon, see celadonpharma.co.uk LVL Health is a leading medical cannabis clinic for chronic pain, providing a rapid access route to the highest quality treatment. Their clinicians prescribe medical cannabis as part of a patient’s pain management care after clinical assessments of safety and efficacy. Both companies have come together to initiate the CANPAIN clinical trial. This trial has been devised to evaluate the efficacy and safety of a defined cannabis-based medicinal product (CBMP) delivered by inhalation to patients with non-cancer chronic pain attending a private clinic. ClinTex have been working with both companies to evaluate the use of CTi to support this ground-breaking clinical trial and a number of areas of potential partnersh...
The Application of ClinTex CTi to accelerate approval of Cannabis Based Medicinal Products
Since 2018, when the UK Home Office announced that cannabis-based medicinal products (CBMPs) were to be moved from Schedule 1 to Schedule 2 status in the misuse of drugs regulations, ClinTex have been closely monitoring associated clinical trials which can help prove that these compounds possess untapped medical utility. One area where current scientific literature contains ample evidence for the successful application of medicinal cannabis are conditions relating to chronic, non-cancer pain. Chronic non-cancer pain is an oft-cited reason for patients who are already using cannabis for medical purposes. Collecting further data on the effectiveness and tolerability of medical cannabis is key in order to potentially pave the way for it’s approval as an NHS treatment in the future. The CANPAIN clinical trial being undertaken by LVL Health, will be a non-randomized, non-blinded real-world trial of the safety, tolerability and effectiveness of a CBMP for the treatment of chronic non-cancer pain compared against matched controls receiving standard of care pain management. The study could run for 3 years but there will be an interim analysis after 12 months with a planned sample size of at least 5000 participants per group, with each patient completing a minimum of 12-months treatment. The CBMP used will be an 8:8 (8% THC, 8% CBD) balanced flower delivered by steam inhalation using a handheld device with flow counting and Bluetoo...